ARTHEx Biotech

Today, we proudly celebrate the International Day of Women and Girls in Science and thank the amazing women on the ARTHEx Biotech Biotech team for their dedication, creativity, and passion. You inspire us every day!   #MyotonicDystrophy #Biotechnology #WomenInScience #InternationalDayOfWomenAndGirlsInScience

ARTHEx Biotech is excited to participate in the 43rd Annual J.P. Morgan Healthcare Conference, which will take place from Monday, January 13th, to Thursday, January 16th, in San Francisco. Take this opportunity to meet with members of the management team in a one-on-one session to discuss our pipeline and our therapeutic approach to leveraging microRNA modulation for the treatment of myotonic dystrophy type 1. https://lnkd.in/d_DTXkh3 #JPM2025 #JPM25 #MyotonicDystrophy #Biotechnology

Merry Christmas and Happy Holidays from all of us at ARTHEx Biotech! This season, we wish you health, happiness, and time with loved ones. Our thoughts remain with those affected by the recent flooding in Valencia, and we hope for brighter days ahead.

We're #hiring a new Sr. Clinical Project Manager in United Kingdom. Apply today or share this post with your network.

We're #hiring a new Clinical Trial Assistant in Spain. Apply today or share this post with your network.

We're #hiring a new Junior Researcher in Valencia, Valencian Community. Apply today or share this post with your network.

Meet Georgina Butler (nee Croswell) of Project Management at ARTHEx Biotech! Born and raised in Cheshire, educated in Newcastle, and now living in London, Georgina brings over 20 years of international project management expertise across the pharmaceutical, biotech, and academic sectors. A pharmacologist by training, she has extensive experience in gene therapy, ophthalmology, neurology, oncology, and cardiovascular research. Since joining ARTHEx just over a year ago, Georgina has enjoyed managing the company’s first clinical trial, ArthemiR™. She has a key role in overseeing multiple aspects of clinical operations and ensures smooth coordination with multiple vendors, all while making a meaningful difference for patients living with myotonic dystrophy type 1 (DM1). Georgina enjoys spending quality time with family and friends outside of work, swimming in the sea, and savoring a hot cup of coffee. Learn more about ARTHEx here: https://lnkd.in/d_DTXkh3 #EmployeeSpotlight #Biotechnology #MyotonicDystrophy

The ARTHEx Biotech team is excited to share that Dr. beatriz llamusi, our Chief Scientific Officer and Co-Founder, will present at the upcoming TIDES: Oligonucleotides and Peptide Therapeutics Europe Annual Meeting, which will be held on November 12-14, 2024, in Hamburg, Germany. We invite you to attend Dr. Llamusí’s presentation to learn more about ARTHEx Biotech's novel delivery method to improve nucleic acid-based therapies transportation to muscle and brain, and how Arthex Biotech is leveraging this delivery strategy inr its innovative antimiRNA treatment for Myotonic Dystrophy type 1 disease. Learn more here: https://lnkd.in/g-acw_w7 #Biotechnology #MyotonicDystrophy #TIDESEurope

DM1 is an aggressive and challenging neuromuscular disorder affecting not only adults, but also children, with no approved treatment option for any age group. ATX-01, the industry’s first anti-microRNA therapeutic developed for DM1, offers a dual mechanism of action which reduces toxic DMPK mRNA while increasing MBNL protein production. With efficient delivery to muscle and brain in preclinical models, we believe ATX-01 has the potential to become a best-in-class therapy for DM1. We are pleased to continue advancing ATX-01 in our Phase I-IIa ArthemiR™ trial, with the goal to bring this therapy to patients. Learn more here: https://lnkd.in/gc6eUau8 #Biotechnology #MyotonicDystrophy #RarePediatricDiseaseDesignation

We are thrilled to announce that ATX-01 has been granted Rare Pediatric Disease (RPD) Designation from the U.S. Food and Drug Administration (FDA) for the treatment of myotonic dystrophy type 1 (DM1). This designation adds to the Orphan Drug Designation (ODD) we previously received from both U.S. and European regulatory authorities for ATX-01 in DM1.   Learn more here: https://lnkd.in/gc6eUau8 #Biotechnology #MyotonicDystrophy #RarePediatricDiseaseDesignation